Encouragingly, the remission depth was independent with MM burden, BCMA+ and CS1+ ratios on MM cells, the levels of sBCMA and serum M protein, R-ISS stage at baseline, and previous treatment including ASCT, CAR-T cells and daratumumab. This evidence concerns the gene MYOM2 and Miyoshi myopathy.